Breast Care最新文献

{"title":"Current Evolutions in Axillary Management.","authors":"Thorsten Kühn, Isabel T Rubio, Oreste D Gentilini, Marjolein Smidt, Jean-Marc Classe","doi":"10.1159/000527823","DOIUrl":"10.1159/000527823","url":null,"abstract":"aWomen’s Clinic, Städtische Kliniken Esslingen a.N, Esslingen, Germany; bBreast Surgical Unit, Clínica Universidad de Navarra, Madrid, Spain; cBreast Surgical Unit, San Raffaele University Hospital, Milan, Italy; dDepartment of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands; eDepartment of Surgery, Institut de Cancerologie de l’Ouest, Saint Herblain, France Received: October 30, 2022 Accepted: October 31, 2022 Published online: December 5, 2022","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801397/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10465496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents Vol. 17, 2022","authors":"B. Gulluoglu","doi":"10.1159/000528398","DOIUrl":"https://doi.org/10.1159/000528398","url":null,"abstract":"Marija Balic, MD – Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria Heba Gamal El Din Mohamed Mahmoud, MD – Surgical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt Theodoros Foukakis, MD – Department of Oncology, Karolinska Institutet and University Hospital, Stockholm, Sweden Alessandra Gennari – Division of Oncology, Maggiore della Carità Hospital, Novara, Italy Bahadir M. Gulluoglu, MD – Department of General Surgery, Marmara University School of Medicine, Istanbul, Turkey Thomas Helbich, MD – Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria Wolfgang Janni, MD – Department of Obstetrics and Gynecology, University Hospital Ulm, Ulm, Germany Eva Johanna Kantelhardt, MD – Department of Gynecology, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany Marion Kiechle, MD – Department of Obstetrics and Gynecology, Technical University Munich, Munich, Germany Ludwig Kiesel, MD – Department of Gynecology and Obstetrics, University Hospital Münster, Münster, Germany Sibylle Loibl, MD – German Breast Group, Neu-Isenburg, Germany Martina Mittlböck, PhD – Center for Medical Statistics, Informatics, and Intelligent Systems, Section for Clinical Biometrics, Medical University of Vienna, Vienna, Austria Shani Paluch-Shimon, MD – Breast Oncology Unit, Department of Oncology, Shaare Zedek Medical Center, Jerusalem, Israel Angelo Paradiso, MD – Experimental Medical Oncology, Istituto Tumori G. Paolo II, IRCCS, National Cancer Institute, Bari, Italy Cristina Saura, MD – Breast Cancer Unit, Medical Oncology Service, Vall d’Hebron University Hospital, Barcelona, Spain Hans-Jörg Senn, MD – Tumor and Breast Center ZeTuP, St. Gallen, Switzerland Günther Steger, MD – Clinical Division of Oncology, Department of Medicine I, Comprehensive Cancer Center of the Medical University of Vienna, Vienna, Austria Janice Tsang, MD – Medical Oncology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Michael Untch, MD – Department of Gynecology, HELIOS Hospital Berlin Buch, Berlin, Germany","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46090301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HER2-Low Breast Cancer: Where Are We?","authors":"Chiara Molinelli, Flavia Jacobs, Caterina Marchiò, Francesca Pitto, Maurizio Cosso, Stefano Spinaci, Evandro de Azambuja, Francesco Schettini, Elisa Agostinetto, Matteo Lambertini","doi":"10.1159/000527391","DOIUrl":"10.1159/000527391","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is traditionally classified into three clinical subtypes based on hormone receptor and HER2 status (i.e., luminal-like, HER2-positive, and triple negative). Each subtype has distinct clinical-pathological and molecular characteristics and requires tailored treatments. Recent research efforts have been focusing on a new classification, identifying the so-called \"HER2-low\" category, including tumors characterized by a low level of HER2 expression (immunohistochemistry score 1+ or 2+ without in situ hybridization amplification). Emerging evidence shows that patients with HER2-low tumors can derive benefit from selected anti-HER2 therapies. This represents a major advancement in the field of breast oncology, where a broader proportion of patients with breast cancer can ultimately benefit from new effective targeted treatment strategies.</p><p><strong>Summary: </strong>The antibody-drug conjugate trastuzumab deruxtecan has proven impressive efficacy in patients with HER2-low breast cancer, and several other drugs are currently under investigation in this subset of patients. Additional investigation is needed to address open issues that exist in this field, including appropriate pathological assessment of HER2-low status, clarification of its prognostic implications, and global access to newly approved drugs.</p><p><strong>Key message: </strong>Our review aims to summarize the available evidence regarding HER2-low breast cancer, illustrating the current challenges that are being addressed and the future perspectives in this exciting new field.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10458812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prepubertal Idiopathic Unilateral Gynecomastia: Case Report and Literature Review.","authors":"Saskia-Laureen Herbert, Katrin Ergezinger, Stephanie Sauer, Florian Kurz, Tanja Schlaiß, Achim Wöckel, Ute-Susann Albert","doi":"10.1159/000525096","DOIUrl":"10.1159/000525096","url":null,"abstract":"<p><strong>Introduction: </strong>Gynecomastia is a benign proliferation of the glandular tissue of the breast in males. Depending on the age, it can be considered a physiological condition. Prepubertal unilateral gynecomastia is a rare phenomenon. There are only a few case reports described through the last few years.</p><p><strong>Case presentation: </strong>We report the clinical appearance and management of prepubertal idiopathic unilateral gynecomastia in a 9-year-old boy. We further include a literature review of 14 cases from 2011 to 2021. In contrast to pubertal gynecomastia, prepubertal gynecomastia and especially unilateral prepubertal gynecomastia are extremely rare conditions. Most cases remain idiopathic.</p><p><strong>Conclusion: </strong>Chromosomal and genetic testing, as well as oncological, endocrine diagnostic and tests for liver and kidney function should be performed. In case of idiopathic prepubertal gynecomastia, surgery is an important part of therapy since patients suffer from their atypical and rare phenotype.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10458815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lack of Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in Early Breast Cancer.","authors":"Maria Del Rosario Sifón, Nicolas Marcolini, Maria Julia Barber, Ignacio Mclean, Manglio Rizzo, Sergio Rivero, Maria Victoria Costanzo, Adrian Nervo, Gabriel Crimi, Florencia Perazzo, Estrella Mariel Levy, Pablo Mandó","doi":"10.1159/000525287","DOIUrl":"10.1159/000525287","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is a highly heterogeneous disease with large differences in the risk of recurrence. An elevated neutrophil-to-lymphocyte ratio (NLR) is correlated with a poor prognosis in a variety of tumors, and although it is still controversial in breast cancer, there are multiple studies, including meta-analysis, suggesting this. The purpose of this study was to analyze the prognostic value of preoperative NLR in an Argentine population of patients with nonmetastatic breast cancer, not exposed to neoadjuvant treatment.</p><p><strong>Methods: </strong>Retrospective multicenter cohort study that includes patients over 18 years of age from three centers in the city and province of Buenos Aires who have had surgery for early breast cancer between January 1, 1999, and December 31, 2014. Based on the previous literature, a cutoff value of 2.0 was defined.</p><p><strong>Results: </strong>A total of 791 patients were eligible for the analysis. Median age was 55 years (IQR 45-65). Median NLR was 1.92 (IQR 1.50-2.56). The distribution of groups according to the 8th edition of the AJCC was 54.1% for stage I, 35.6% stage II, and 10.4% stage III. Among the different tumor phenotypes, 79.0% were HR+/HER2-, 11.4% were HR+ or-/HER2+, and 9.2% were HR-/HER2-. With a median follow-up of 5.3 years, 112 patients (14.2%) had disease recurrence. Stage III patients had a higher NLR than stage I and stage II patients (<i>p</i> = 0.002). The rest of the clinical and pathological characteristics did not show differences in the groups according to NLR. There were no differences in relapse-free survival according to the NLR (<i>p</i> = 0.37), and it did not change after adjusting for other prognostic variables.</p><p><strong>Conclusion: </strong>We consider it is important to determine the efficacy of prognostic markers that are easily accessible and of simple, systematic application. However, NLR does not appear to be an independent prognostic factor for recurrence in our population. In this sense, we consider it is important to publish negative results in order to avoid publication bias.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10465903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PharmaNews","authors":"","doi":"10.1159/000528381","DOIUrl":"https://doi.org/10.1159/000528381","url":null,"abstract":"Ab sofort ist der Poly(ADP-Ribose)-Polymerase (PARP)-Inhibitor Niraparib auch als Filmtablette verfügbar. Niraparib ist damit für eine Übergangsfrist bis voraussichtlich Ende des Jahres sowohl als Filmtablette als auch als Hartkapsel erhältlich für die Monotherapie erwachsener Patientinnen mit fortgeschrittenem epithelialem (FIGO-Stadien III und IV) hochgradigem Karzinom der Ovarien, der Tuben oder mit primärem Peritonealkarzinom, die nach einer Platin-basierten Erstlinien-Chemotherapie ein Ansprechen (komplett oder partiell) haben, sowie für die Monotherapie erwachsener Patientinnen mit Rezidiv eines Platin-sensiblen, hochgradigen serösen epithelialen Karzinoms der Ovarien, der Tuben oder mit primärem Peritonealkarzinom, die sich nach einer Platin-basierten Chemotherapie in Remission (komplett oder partiell) befinden [1, 2]. Die neue Tablettenformulierung ist bioäquivalent mit der bisher verfügbaren Hartkapsel und enthält die gleiche Wirkstoffmenge; Behandlungsschema, Wirksamkeit und Sicherheitsprofil sind unverändert [1, 2]. Die Niraparib Filmtablette ist kleiner als die Hartkapsel, beinhaltet keine Gelatine, weniger Laktose und keinen Farbstoff E102 [1, 2]. Die Tablettenformulierung ist seit 01.10.2022 in der Lauer-Taxe gelistet und wird die Hartkapsel als Darreichungsform ablösen.","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41451873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kombinationstherapie bei HER2+ mBC","authors":"N. Marschner","doi":"10.1159/000528380","DOIUrl":"https://doi.org/10.1159/000528380","url":null,"abstract":"information@karger.com www.karger.com besonders bemerkenswert vor dem Hintergrund der Tatsache, dass 13% der Studienteilnehmer vom Placebo-Arm in die Verum-Gruppe gewechselt waren», führte Dr. Norbert Marschner, Freiburg, aus. Die 2-Jahres-Überlebensraten betrugen jeweils 51% (Tucatinib-Arm) bzw. 40% (Abb. 1) [2]. Das PFS lag bei 7,6 Monaten unter der TucatinibKombinationstherapie gegenüber 4,9 Monaten im Placebo-Arm (HR = 0,57; 95%KI: 0,47–0,70; p < 0,00001; sekundärer Endpunkt) [2]. Nach einer Beobachtungszeit von 1 Jahr lag der Anteil der Studienpatienten mit PFS bei 29% unter der Tucatinib-Kombinationstherapie bzw. 14% im Placebo-Arm [2]. «Die Ergebnisse sowohl im OS als auch im PFS zeigen die hohe Wirksamkeit der Tucatinib-Kombinationstherapie bei diesen Patienten mit fortgeschrittener Erkrankung», erklärte Dr. Marschner.","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44242643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metaplastic Breast Cancer: Mesenchymal Subtype Has Worse Survival Outcomes.","authors":"Enver Özkurt, Selman Emiroğlu, Neslihan Cabioğlu, Hasan Karanlık, Semen Önder, Mustafa Tükenmez, Abdullah İğci, Vahit Özmen, Mahmut Müslümanoğlu","doi":"10.1159/000525324","DOIUrl":"10.1159/000525324","url":null,"abstract":"<p><strong>Background: </strong>Metaplastic breast carcinoma (MBC) is a rare type of breast cancer that accounts for 0.2-1% of all breast cancers. To date, there are only few institutional studies comparing survival rates between different subtypes. In this retrospective cohort study, we aim to evaluate factors effecting survival rates of different subtypes of MBC.</p><p><strong>Methods: </strong>This retrospective cohort study observed 118 nonmetastatic MBC patient records extracted from 15,244 breast cancer cases between December 2000 and December 2020. In order to analyze factors effecting survival rates of mesenchymal subtype of MBC, all cases are classified as mesenchymal (<i>n</i> = 45) and other (<i>n</i> = 48). Twenty-five cases could not be sub-classified due to the missing data. Univariate and multivariate logistic regression analyses were performed to define factors associated with survival rates.</p><p><strong>Results: </strong>Of the 15,244 cases, 118 (0.8%) were nonmetastatic MBC. 105 were triple negative and 12 were nonluminal HER2. There was no significant difference between mesenchymal and other subgroups for age, median tumor size, AJCC staging, and type of surgery. Of the five local recurrences with known subgroup, four of them had mesenchymal subtype. It is demonstrated that mesenchymal subtype was significantly associated with worse 5-year disease-free survival and disease-specific survival (HR: 2.35 [1.01-5.48], <i>p</i> = 0.049, and HR: 3.16 [1.06-9.47], <i>p</i> = 0.040 with 95% CI, respectively).</p><p><strong>Conclusion: </strong>This study is one of the few studies presenting the survival outcomes of subtypes of MBCs. Nonetheless, it is the only study demonstrating that mesenchymal subtype had worse survival outcomes. Further studies are needed to determine the outcome of different subtypes of MBCs.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10458813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining Therapy in Patients with HER2-Positive Breast Cancer with Central Nervous System Metastasis.","authors":"Marta Filipa Freire Vaz Batista, Inês Eiriz, Amanda Fitzpatrick, Fanny Le Du, Sofia Braga, Diogo Alpuim Costa","doi":"10.1159/000526431","DOIUrl":"10.1159/000526431","url":null,"abstract":"<p><strong>Background: </strong>Brain metastasis (BM) is a major clinical problem in metastatic breast cancer (MBC), occurring in 50% of patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Historically omitted from clinical trials, recent studies of novel HER2-targeted agents have focused on HER2+ BM patients, addressing stable but also progressing BM and leptomeningeal carcinomatosis (LMC).</p><p><strong>Summary: </strong>This review aimed to summarize the most relevant data on treating patients with HER2+ BM and LMC.</p><p><strong>Key messages: </strong>The treatment paradigm for patients with HER2+ MBC has changed. Local therapies play an important role, but accumulating evidence on the intracranial activity and clinical benefit of anti-HER2 targeting therapies might lead to a shift in the paradigm on treating BM in the next few years towards more widespread use of systemic therapy.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9154067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating HEmopatch® in Reducing Seroma-Related Complications following Axillary Lymph Node DIssection: A Pilot Study (HEIDI).","authors":"Merel A Spiekerman van Weezelenburg, Lisa de Rooij, Loeki Aldenhoven, Pieter P H L Broos, Sander M J van Kuijk, Elisabeth R M van Haaren, Alfred Janssen, Yvonne L J Vissers, Geerard L Beets, James van Bastelaar","doi":"10.1159/000525839","DOIUrl":"10.1159/000525839","url":null,"abstract":"<p><strong>Purpose: </strong>Axillary lymph node dissection (ALND) is performed to treat locoregional metastatic disease in breast cancer and melanoma patients. However, it is notorious for its complications, most commonly seroma formation and its sequelae. Ample research has been done to evaluate seroma formation after ALND; these results, however, have not been conclusive. Hence, this pilot study aimed to evaluate a readily available haemostatic patch, Hemopatch®, to assess its effect on seroma formation following ALND.</p><p><strong>Methods: </strong>In this pilot study, a prospective cohort of 20 patients receiving Hemopatch® following ALND was compared to a retrospective cohort of patients who underwent ALND between 2014 and 2019. The primary outcome measure was the number of patients developing clinically significant seroma (CSS) after ALND. Additionally, the number of wound complications, subsequent interventions, additional outpatient clinic visits, and drain output was assessed. Differences between groups were deemed clinically relevant if the proportions differed >50% between groups.</p><p><strong>Results: </strong>In total, 20 prospective and 42 retrospective patients were included. In the Hemopatch® group, 30% of the patients developed CSS, compared to 43% in the control group. Three patients in both groups developed a surgical site infection. Thirty-five percent of patients in the Hemopatch® group required additional unscheduled visits versus 62% of patients in the control group.</p><p><strong>Conclusion: </strong>The application of Hemopatch® after ALND did not lead to a clinically relevant reduction of CSS and wound complications. However, fewer Hemopatch® patients required additional outpatient clinic visits. Due to the limited amount of participants, the true value of Hemopatch® in ALND remains unclear.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10458816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}